GeneDx Holdings Corp. Operating Lease, Impairment Loss
GeneDx Holdings Corp. (WGS) reported Operating Lease, Impairment Loss of $10.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseImpairmentLoss · last filed 2023-03-16
- GeneDx Holdings Corp. operating lease, impairment loss for fiscal 2022 was $10.00M.
| Period end | Operating Lease, Impairment Loss 12 month |
|---|---|
| 2022-12-31 | $10.00M 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |